Abstract
As mentioned in the comment, the efficacy of neoadjuvant chemotherapy (NAC) in the treatment of urothelial carcinoma has been the therapy of choice since Grossman et al in 2003 demonstrated a significant benefit in overall survival in downstaged patients with NAC followed by cystectomy compared to cystectomy alone for muscle-invasive bladder cancer.1 However, prior literature has delineated significant differences in treatment effects between urothelial cancer of the bladder compared to upper tract urothelial cancer (UTUC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
